Patients with heart failure and LVEF less than 35% and NYHA FC II and more will be selected . Primary data including echocardiographic measures and laboratory data including BS, Uric acid , Cr, BUN , CRP , CBC , Total Chl , TG , LDL , HDL , Bil (T and D) , AST , ALT and 6-minute walk test and complete history taking will be taken . Drug history of patients will be scrutinized and will be adjusted so that every patient taking at least the standard 4-drug heart failure regimen at least for 2 weeks . According to inclusion and exclusion criteria patients will be entered to the study and randomly assigned into two groups . Drug and placebo will be started with 25mg single dose at bedtime and gradually increasing upto maximum dosage of 50mg twice daily. Patients will be visited at 2 , 4 , 8 and 12 weeks and monitored for vital signs , probable adverse drug reactions and all the clinical and paraclinical data will be examined again at the end of the survey and collected data will be analyzed . In addition if during the follow up visits , any adverse reaction or intolerance were seen , the patient will quit from the study.